Does Rallies show Form 4 insider transactions for TCRX?

Yes. Rallies tracks TCRX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is TCRX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for TCRX. It does not provide personalized investment advice.

TCRX (TScan Therapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

TScan Therapeutics, Inc. Common Stock (TCRX) is a publicly traded Healthcare sector company. As of May 21, 2026, TCRX trades at $0.99 with a market cap of $65.35M and a P/E ratio of -1.05. TCRX moved +3.26% today. Year to date, TCRX is -4.37%; over the trailing twelve months it is -17.80%. Its 52-week range spans $0.88 to $6.23. Analyst consensus is strong buy with an average price target of $6.00. Rallies surfaces TCRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading TCRX stock inside the company?

Recent TCRX insider activity includes Lynx1 Capital Management LP bought 6.23K, Lynx1 Capital Management LP bought 75.50K, Lynx1 Capital Management LP bought 80.07K, Lynx1 Capital Management LP bought 1.20M, and Lynx1 Capital Management LP bought 1.39M. Rallies tracks insider transaction dates, shares, prices, and estimated values.

TCRX Key Metrics

Key financial metrics for TCRX
Metric	Value
Price	$0.99
Market Cap	$65.35M
P/E Ratio	-1.05
EPS	$-0.96
Dividend Yield	0.00%
52-Week High	$6.23
52-Week Low	$0.88
Volume	2
Avg Volume	0
Revenue (TTM)	$9.14M
Net Income	$-124.31M
Gross Margin	0.00%

Recent TCRX Insider Trades

Lynx1 Capital Management LP bought 6.23K (~$5.60K) on Dec 23, 2025.
Lynx1 Capital Management LP bought 75.50K (~$67.95K) on Dec 22, 2025.
Lynx1 Capital Management LP bought 80.07K (~$71.97K) on Dec 19, 2025.
Lynx1 Capital Management LP bought 1.20M (~$1.44M) on May 20, 2025.
Lynx1 Capital Management LP bought 1.39M (~$1.67M) on May 19, 2025.

Latest TCRX News

TScan Q1 Net Loss $28.7M, $128.1M Cash Funds Q2 Phase 3 Study — May 6, 2026
TScan to Present CD45-Targeted TCR-T Therapy Abstract at ASGCT Meeting — Apr 27, 2026

TCRX Analyst Consensus

6 analysts cover TCRX: 0 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $6.00.

Common questions about TCRX

Who is trading TCRX stock inside the company?: Recent TCRX insider activity includes Lynx1 Capital Management LP bought 6.23K, Lynx1 Capital Management LP bought 75.50K, Lynx1 Capital Management LP bought 80.07K, Lynx1 Capital Management LP bought 1.20M, and Lynx1 Capital Management LP bought 1.39M. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for TCRX?: Yes. Rallies tracks TCRX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is TCRX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for TCRX. It does not provide personalized investment advice.